Showing results (11-20 of 93) with videos related to
Sort By:
Pageof 10
Immunity|July 21, 2017
The P2X7 Receptor in Infection and InflammationFrancesco Di Virgilio, Diego Dal Ben, Alba Clara Sarti, et al.Biochemistry|June 9, 2004
Interaction model for anthracycline activity against DNA topoisomerase IIStefano Moro, Giovanni L Beretta, Diego Dal Ben, et al.EJNMMI Research|April 5, 2017
Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel 18F-labelled PET tracer targeting P2X7Enrico Raffaele Fantoni, Diego Dal Ben, Simonetta Falzoni, et al.Bioorganic & Medicinal Chemistry|October 15, 2010
Molecular modeling study on potent and selective adenosine A(3) receptor agonistsDiego Dal Ben, Michela Buccioni, Catia Lambertucci, et al.Bioorganic Chemistry|January 31, 2026
Adenine nucleotides as potent and selective GPR17 modulatorsDiego Dal Ben, Catia Lambertucci, Michela Buccioni, et al.Expert Opinion on Therapeutic Patents|April 7, 2022
A patent review of adenosine A2B receptor antagonists (2016-present)Beatrice Francucci, Diego Dal Ben, Catia Lambertucci, et al.Journal of Medicinal Chemistry|February 1, 2008
Synthesis and antitumor evaluation of bis aza-anthracene-9,10-diones and bis aza-anthrapyrazole-6-onesIppolito Antonini, Giorgio Santoni, Roberta Lucciarini, et al.Chemmedchem|December 21, 2006
Highlights on the development of A(2A) adenosine receptor agonists and antagonistsGloria Cristalli, Barbara Cacciari, Diego Dal Ben, et al.Molecules (Basel, Switzerland)|March 6, 2021
Combined Therapy of A1AR Agonists and A2AAR Antagonists in NeuroinflammationGabriella Marucci, Diego Dal Ben, Catia Lambertucci, et al.Expert Opinion on Therapeutic Patents|November 16, 2019
Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applicationsGabriella Marucci, Diego Dal Ben, Michela Buccioni, et al.Pageof 10